机构：[a]Innovation Center for Neurological Disorders, Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, P.R.China内科系统神经内科神经科系统江苏省人民医院首都医科大学宣武医院神经疾病高创中心（北京学者工作室）神经内科[b]Department of Neurology, the Affiliated Hospital of Guizhou Medical University, Guizhou, P.R.China内科系统神经内科江苏省人民医院[c]Department of Neurology, Shandong Provincial Hospital, Jinan, P.R.China内科系统神经内科江苏省人民医院[d]Department of Neurology, the Henan Provincial Peoples Hospital, Zhengzhou, P.R.China内科系统神经内科江苏省人民医院[e]Department of Neurology, the First Hospital of Jilin University, Jilin, P.R.China内科系统神经内科江苏省人民医院[f]Department of Neurology, Baotou Central Hospital, Baotou, P.R.China内科系统神经内科江苏省人民医院[g]Department of Neurology, the First Affiliated Hospital of Guangxi Medical University, Nanning, P.R.China内科系统神经内科江苏省人民医院[h]Department of Neurology, the Second Hospital of Hebei Medical University, Shijiazhuang, P.R.China内科系统神经内科江苏省人民医院
Introduction: Neuronal-derived exosomal A beta 42, T-tau, and P-T181-tau have been demonstrated to be biomarkers of Alzheimer's disease (AD). However, no study has assessed the association of A beta 42, T-tau, and P-T181-tau between exosomes and CSF. Methods: This was a multicenter study with two-stage design. The subjects included 28 AD patients, 25 aMCI patients, and 29 controls in the discovery stage; the results of which were confirmed in the validation stage (73 AD, 71 aMCI, and 72 controls). Results: The exosomal concentrations of A beta 42, T-tau, and P-T181-tau in AD group were higher than those in aMCI and control groups (all P < .001). The level of each exosomal biomarker was highly correlated with that in CSF. Discussion: This study verified the agreement between CSF and blood exosomal biomarkers and confirmed that exosomal A beta 42, T-tau, and P-T181-tau have the same capacity as those in CSF for the diagnosis of AD and aMCI. (C) 2019 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer's Association.
基金：
Key Project of the National Natural Science Foundation of China [81530036]; National Key Scientific Instrument and Equipment Development Project [31627803]; Mission Program of Beijing Municipal Administration of Hospitals [SML20150801]; Beijing Scholars Program; Beijing Brain Initiative from Beijing Municipal Science & Technology Commission [Z161100000216137]; CHINA-CANADA Joint Initiative on Alzheimer's Disease and Related Disorders [81261120571]; Beijing Municipal Commission of Health and Family Planning [PXM2018_026283_000002]
第一作者机构：[a]Innovation Center for Neurological Disorders, Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, P.R.China
通讯作者：
通讯机构：[a]Innovation Center for Neurological Disorders, Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, P.R.China
推荐引用方式(GB/T 7714)：
Longfei Jia,Qiongqiong Qiu,Heng Zhang,et al.Concordance between the assessment of A beta 42, T-tau, and P-T181-tau in peripheral blood neuronal-derived exosomes and cerebrospinal fluid[J].ALZHEIMERS & DEMENTIA.2019,15(8):1071-1080.doi:10.1016/j.jalz.2019.05.002.
APA：
Longfei Jia,Qiongqiong Qiu,Heng Zhang,Lan Chu,Yifeng Du...&Jianping Jia.(2019).Concordance between the assessment of A beta 42, T-tau, and P-T181-tau in peripheral blood neuronal-derived exosomes and cerebrospinal fluid.ALZHEIMERS & DEMENTIA,15,(8)
MLA：
Longfei Jia,et al."Concordance between the assessment of A beta 42, T-tau, and P-T181-tau in peripheral blood neuronal-derived exosomes and cerebrospinal fluid".ALZHEIMERS & DEMENTIA 15..8(2019):1071-1080
医学